We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
- Authors
Nagayama, H; Takahashi, S; Takahashi, T; Ogami, K; Ikebuchi, K; Tojo, A; Tani, K; Asano, S
- Abstract
Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.
- Subjects
ACUTE myeloid leukemia; LEUKEMIA; BONE marrow transplantation; HOMOGRAFTS
- Publication
Bone Marrow Transplantation, 1999, Vol 23, Issue 2, p183
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1701550